111 Unveils New Video on The Impact of Chinese Policies to Medical Industry

SHANGHAI,Jan. 19,2020 --111,Inc. (NASDAQ: YI) ("111" or the "Company"),a leading integrated online and offline healthcare platform,announced the release of the sixth episode in its 111 Insight series. The title announced today,The Impact of Chinese Policies to Medical Industry,is hosted by Dr. Gang Yu,Co-Founder and Executive Chairman of 111,Inc. Dr. Yu will moderate a discussion with Dr. Xiaobin Wu,President of BeiGene Ltd,and Dr. Darren Ji,CEO of Elpiscience Biopharma,Ltd.

Tencent video link: https://v.qq.com/x/page/h3052n5gvqw.html?

The Impact of Chinese Policies to Medical Industrywill feature:

Impacts of China's healthcare reform on the industry: driving a market switch from public hospitals to retail channels and online channels

Purpose of the "4+7" policy: encouraging innovative drugs and reducing the price of patent and generic drugs

The Internet and the online retail will play big roles to make accessible for drugs

The 111 Insight series is produced by 111,Inc. and is hosted by Dr. Gang Yu,Co-Founder and Executive Chairman,and Mr. Junling Liu,Co-Founder,Chairman and CEO. The series focuses on important topics in global health and the state of the industry in China through interviews with industry experts,investors,and healthcare professionals.

China's healthcare industry in China is evolving rapidly and there is increasing global interest in China's health reform and policies. Among the topics that will be discussed throughout the series are: How the Internet is reshaping China's healthcare industry and pharmaceutical delivery market; how new government policies and regulations impact the healthcare industry; how new technologies are changing private health insurance; and the opportunities and challenges facing China's aging population.

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934,as amended,and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "target," "confident" and similar statements. Among other things,the Business Outlook and quotations from management in this announcement,as well as 111's strategic and operational plans,contain forward-looking statements. 111 may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission,in its annual report to shareholders,in press releases and other written materials and in oral statements made by its officers,directors or employees to third parties. Such statements are based upon management's current expectations and current market and operating conditions and relate to events that involve known or unknown risks,uncertainties and other factors,all of which are difficult to predict and many of which are beyond the Company's control. Forward-looking statements involve inherent risks,uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. Potential risks and uncertainties include,but are not limited to,uncertainties as to the Company's ability comply with extensive and evolving regulatory requirements,its ability to compete effectively in the evolving PRC general health and wellness market,its ability to manage the growth of its business and expansion plans,its ability to achieve or maintain profitability in the future,its ability to control the risks associated with its pharmaceutical retail and wholesale businesses,and the Company's ability to meet the standards necessary to maintain listing of its ADSs on the Nasdaq Global Market,including its ability to cure any non-compliance with Nasdaq's continued listing criteria. Further information regarding these and other risks,uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release,and 111 does not undertake any obligation to update any forward-looking statement as a result of new information,future events or otherwise,except as required under applicable law.

About 111,Inc.

111,Inc. (NASDAQ: YI) ("111" or the "Company") is a leading integrated online and offline healthcare platform in China. The Company provides hundreds of millions of consumers with better access to pharmaceutical products and medical services directly through its online retail pharmacy and indirectly through its offline pharmacy network. 111 also offers online medical services through its Internet hospital,1 Clinic,which provides consumers with cost-effective and convenient online consultation and electronic prescription services. In addition to providing direct services to consumers through its online retail pharmacy,111 also enables offline pharmacies to better serve their customers. The Company's online wholesale pharmacy,1 Drug Mall,serves as a one-stop shop for pharmacies to source a vast selection of pharmaceutical products. The Company's New Retail platform,by integrating the front and back ends of the pharmaceutical supply chain,has formed a smart supply chain,which transforms the flow of pharmaceutical products to pharmacies and modernizes how they serve their customers.

For more information on 111,please visit http://ir.111.com.cn/

For more information,please contact:

111,Inc.

Ms. Monica Mu

IR Director

ir@111.com.cn

Christensen

In China

Mr. Christian Arnell

Phone: +86-10-5900-1548

E-mail: carnell@christensenir.com

In U.S.

Ms. Linda Bergkamp

Phone: +1-480-614-3004

Email: lbergkamp@ChristensenIR.com

View original content:/news-releases/111-unveils-new-video-on-the-impact-of-chinese-policies-to-medical-industry-300989308.html